Monday, June 23, 2025 6/23/2025

Targeting dsRNA sensing and ADAR1 in melanoma

Award Number: R37CA279834
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2024
PERIOD OF PERFORMANCE END DATE: 02/28/2029

Group Awards By:

View Award Description

Targeting dsRNA sensing and ADAR1 in melanoma - PROJECT SUMMARY: Over the past decade the development of immune checkpoint blockade (ICB) in melanoma and other tumor types has transformed the treatment options available for many patients with cancer. However, within melanoma only approximately half of patients experience a durable response to treatment, with worse results in most other tumor types. We and others have identified strategies to enhance anti-tumor immunity and sensitize non-responsive murine melanoma tumors to ICB by targeting dsRNA pattern recognition receptors (PRRs). These strategies include the agonism of the dsRNA sensor RIG-I and the loss of Adenosine Deaminase Acting on dsRNA (ADAR1). We showed that ADAR1 is an innate inhibitory checkpoint in tumor cells that limits anti-cancer immunity, and that targeting it therapeutically can trigger multiple dsRNA PRRs to sensitize tumors to immunotherapy. Both RIG-I agonism and targeting ADAR1 resulted in enhanced cytokine release in murine tumor microenvironments and improved the recruitment and control of tumors by T cells. In recent work we have uncovered evidence that co-targeting multiple dsRNA sensing pathways induces cooperative effects and enhances anti-tumor immunity compared with targeting single sensors. However, several gaps in knowledge limit the translation of these strategies into effective therapies for patients. These include: i) defining the optimal therapeutic strategy for targeting dsRNA PRRs; ii) understanding mechanisms by which dsRNA sensing in tumors programs immune cell function; and iii) identifying the patients most likely to respond to dsRNA-targeting therapeutics. To test the effects of dsRNA PRR stimulation on patient tumor and immune samples ex vivo, we developed a novel perturbational single cell RNA sequencing approach. Applying this strategy, we found that dsRNA stimulation of patient tumor and immune cells induces distinct T cell programs of activation and survival and that these approaches may be most effective in tumors with high pre-treatment levels of interferon signaling and adenosine-to-inosine dsRNA editing. In Aim 1 of this proposal, we will test the hypothesis that co-targeting ADAR1 and RIG-I enhances the activation, proliferation and function of anti-tumor T cells. We will explore mechanisms of this finding in mouse models including the increased recruitment, activation and cross-presentation of tumor antigens by dendritic cells. In Aim 2 we will seek to identify the tumor determinants of therapeutic response to targeting ADAR1 and uncover insights that will facilitate the development of small molecule and nucleic acid therapeutics. If successful, the work described in this proposal will help define the rules by which tumors and T cells respond to dsRNA stimulation and advance the development of dsRNA-targeting strategies for melanoma and other tumors.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $631,778 )
2025	2025	YALE UNIV	150 MUNSON ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Cancer Treatment Research	000	2	2/28/2025	NON-COMPETING CONTINUATION	$568,602
2025	2025	YALE UNIV	150 MUNSON ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Cancer Treatment Research	001	2	5/22/2025	NON-COMPETING CONTINUATION	$63,176
														Subtotal = $631,778

Issue Date FY: 2024 ( Subtotal = $631,778 )
2024	2024	YALE UNIV	150 MUNSON ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Cancer Treatment Research	000	1	2/22/2024	NEW	$631,778
														Subtotal = $631,778

Grand Total All Awards = $1,263,556

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting dsRNA sensing and ADAR1 in melanoma

Award Number: R37CA279834

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2024

PERIOD OF PERFORMANCE END DATE: 02/28/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer